CALIBR will receive access to EXCELRA’s GOSTAR® database under this agreement.
HYDERABAD, India (BUSINESS WIRE) Excelra Knowledge Solutions Pvt. Ltd. (EXCELRA) announced that it has entered into a database license agreement with California Institute of Biomedical Research (CALIBR). GOSTAR® is a manually curated small molecule SAR database that has been developed by a team of over 200 scientists, over the past 14 years. The database contains over 7 million compounds manually curated from over 3 million patents and 400,000 journals, and contains over 21 million associated SAR data points. Anandbir Singh Brar, CEO at EXCELRA was elated to talk on the development and noted, “Our collaboration has started gaining the momentum required to deliver unprecedented results. This is just the beginning. GOSTAR® has been a catalyst to the research success of a lot of our customers. Our platform capabilities will definitely add value to CALIBR’s ecosystem. We are really excited about this collaboration and keen to see CALIBR derive the true potential of GOSTAR®.” Arnab Chatterjee, VP, Medicinal Chemistry at CALIBR quoted, “The GOSTAR® database has been instrumental to our drug profiling and repurposing efforts, and we look forward to expanding the utility to enable our other platforms.”
About EXCELRA
EXCELRA is a leading Informatics and Analytics solutions provider for the life-science community that assists customers worldwide make informed research decisions by harnessing the power of data and analytics. With experience in custom data annotation, knowledgebase development and maintenance, SAR, biomarkers, and clinical outcomes EXCELRA caters to 150+ clients worldwide. EXCELRA’s Pharma Analytics division supports decision making at all levels of drug development by providing computational biology, portfolio strategy and pipeline planning support. For more information, see stg-excelrastage2-ver3.kinsta.cloud
About CALIBR
The California Institute for Biomedical Research (CALIBR) is an independent not-for-profit institute established in 2012 with the goal of accelerating the translation of basic research to new medicines that address unmet medical needs. Collaborations with researchers across the world expedite the translation of basic biomedical findings to new candidate therapeutics, while enabling commercial partnerships are formed to bring these new medicines to the public. Value created from these activities is reinvested in preclinical and clinical research at the institute to further its mission.
